Navigation Links
Judge Rejects Quigley's Claims - Karkus Director Candidates Prevail in Federal Court

WOODMERE, N.Y., May 18 /PRNewswire/ -- The United States District Court issued a decision and order Friday afternoon rejecting The Quigley Corporation's (Nasdaq: QGLY) attempt to prevent Ted Karkus, Mark Burnett, John DeShazo, Mark Frank, Louis Gleckel, MD, Mark Leventhal, and James McCubbin ("the Shareholder Nominees") from continuing their efforts to allow Quigley's shareholders to choose whether to vote to replace the current board.

The Federal Court's decision followed a hearing on the Company's assertions. The Company had launched a court battle in an effort to block the Shareholder Nominees from soliciting your vote. As a result of the Court's ruling on Friday, all shareholders remain free to vote for change by voting on the lightly shaded BLUE Voting Instruction Form for the highly qualified slate of Shareholder Nominees.

The annual meeting is just two days away. To help you decide on how to vote, we have provided our thoughts on some important questions all shareholders should consider regarding the actions of Guy Quigley and the incumbent directors, and the Court's findings:

Question: How Did The Court Rule On The Company's Claims That (1) The Shareholder Nominees Had Not Accurately Described The Darius/Innerlight/Gary Quigley Transactions and (2) The Shareholder Nominees Have "Undisclosed Plans" Concerning the Company?

Answer: The Company Voluntarily Withdrew Both of These Claims As A Basis For a Preliminary Injunction.

Explanation: In our proxy materials and our other communications with you we told you about the Darius/Innerlight/Gary Quigley transactions. The Company sued us, claiming that our prior statements to you on this topic were not accurate -- even though our prior statements did little more than summarize and quote prior SEC filings.

Last week, one day before the hearing before the federal court, we finally had the opportunity to cross-examine both Guy Quigley and Gary Quigley regarding the Darius/Innerlight/Gary Quigley dealings. Not surprisingly, the next day, Guy Quigley did not testify in Court and Gary Quigley did not even show up in Court, much less testify -- and the Company dropped those claims as a basis for a preliminary injunction.

Question: How Did The Court Rule On The Company's Claim That There Are "Undisclosed" Members of the Karkus Group?

Answer: The Court Rejected That Claim As Being Wholly Unsupported By The Facts.

Explanation: Here is some of what the Court said:

"Even allowing for an indulgent use of circumstantial evidence and recognizing that direct, 'smoking gun' evidence, much less an admission of an agreement, would be highly unlikely to unearth, Quigley's claim that Mr. Ligums has agreed to act as a member of the Karkus group to act in deliberate concert with Mr. Karkus and others to unseat the current Quigley board remains nothing more than a claim fed by unwarranted assumptions, innuendo and suspicion, but unsupported by any pertinent fact."

The Court noted the "decided lack of evidence presented by Quigley to support its claim...."

What Should Shareholders Do, Now That The Court Has Ruled In Favor of The Shareholder Nominees?

We encourage you to vote for the Shareholder Nominees using the lightly shaded BLUE Voting Instruction Form. Exercise your rights as shareholders to support the Shareholder Nominees, rights that the Shareholder Nominees fought hard and at great expense to win for all shareholders. Below are just some of the reasons:

REASON NUMBER ONE: The Unwarranted Costs Charged to The Company In Trying To Prevent An Open Election.

  • This lawsuit has cost shareholders an enormous amount of money. How much of your Company's treasury has been tapped in a failed attempt to prevent us from offering you a choice in this election?
  • What purpose was served by bringing this lawsuit other than to try and prevent you, the shareholders, from having the ability to vote for new board members and to vote for change?

REASON NUMBER TWO: The Facts Regarding the Darius/Innerlight/Gary Quigley Transactions Show That Darius Is A Money-Maker And Gary Quigley Has Significant Interests in Darius.

  • It remains undisputed that Gary Quigley, brother of Chairman Guy Quigley, shows up as a large stockholder in Innerlight Holdings within days of the sale to Innerlight. And, we still do not understand why "royalties" are paid by Innerlight to ScandaSystems, an offshore company in which Gary Quigley is disclosed to be a principal and a major stockholder.
  • It remains undisputed that the incumbent board approved the Darius/Innerlight transaction.
  • It remains undisputed that they permitted the sale of Darius for a mere $1 million in cash plus assumption of certain Darius obligations, even though Darius had turned around and was profitable before the sale.
  • It remains undisputed that the buyer, Innerlight Holdings, has filed statements with the SEC reporting that the Darius business went on to generate impressive revenues and profits in 2008.
  • The Innerlight Holdings registration statements reported net sales of $2.188 million and Income from Operations of $131,369 for Darius (Innerlight Inc.) for the first two months of 2008 (before the sale).
  • That registration statement reported net sales of $14,556,000 and Income from Operations of $2.507 million for Innerlight Holdings for the remainder of 2008 (after the sale).
  • Your Company, The Quigley Corporation, received just $1 million dollars cash for Darius/Innerlight Inc.
  • Is that really all that Darius was worth? Why does Gary Quigley receive royalty payments from Innerlight Holdings?

Should you rely on the current board to approve appropriate strategic initiatives, licensing deals, royalty deals, and divestitures in the future given their handling of the Darius transaction?

REASON NUMBER THREE: The Future of Your Company Is At Stake.

  • Spending on Research and Development has continued to shrink. Under the current Board's stewardship, in the first quarter of 2009, the Company spent less than $250,000 on R&D while losing over $2 million.
  • Wouldn't the enormous amount of money spent in litigation trying to prevent us from seeking Board seats have been better spent on R&D?
  • With the incumbent board, will excessive compensation to management and their family members continue? Will the decline in revenues and posting of losses continue? Will shareholders' equity continue to drop? Will R&D spending continue to decline?

As shareholders, we need to make changes to our Board of Directors NOW before the situation gets even worse. We simply CANNOT afford to let this continue.

REASON NUMBER FOUR: Can You Believe What The Incumbents Tell You?

  • In a press release and letter to you dated May 7th, the Company told you the following:

"... at no point in time has either Guy Quigley, or Charles Phillips cashed in their respective equity ownership in the Company for personal gain."

In fact, according to Form 4 disclosure statements that Guy Quigley and Charles Phillips filed with the SEC, in 2006 they each sold 375,000 shares of Company stock and collectively received proceeds of over $6 million. Does this sound to you like they never "cashed in their respective equity ownership in the Company for personal gain"?

REASON NUMBER FIVE: We Are Invested In Your Company.

  • The incumbent outside directors own a total of 500 shares of stock. They have no real investment in your Company.
  • By contrast, the Shareholder Nominees own 1,309,323 shares of stock that were bought and paid for with their own funds. We are long term investors in the Company. We only profit if you profit.
  • We are exercising our right to nominate and vote for a new Board of Directors to protect your investment and ours. We hope that you appreciate and support our earnest efforts.
  • We have no current interest or plans to restructure the Company or sell off any operations. The current board missed this opportunity a long time ago. Cold-Eeze revenues have dropped so precipitously, and market conditions have changed so dramatically, that we just don't believe that now is the time to divest any assets.
  • Our goal is to stabilize OTC revenues, eliminate excessive compensation and make sure overhead is in line with revenues so that we can return to profitability and allow the Company to increase, rather than decrease, critical R&D spending. Elect a strong and experienced Board of Directors by voting for the Shareholder Nominees. Let us return our Company's Over-The-Counter products business to profitability and increase R&D spending. Let us implement long term plans to build a valuable Pharma division and a valuable Company.


RiskMetrics Group, the independent institutional proxy advisory firm, stated that "... given its operating performance and corporate governance issues, we believe that dissidents have made a valid case for change."

The Election is in just two days, on May 20th. To vote for our slate, it is simple. Do not vote management's white proxy form. Even if you have already sent in the white proxy, it is not too late to change your vote. Time is running short, and every vote counts. No matter how many shares you hold, please vote today. Your vote is incredibly important to all of us.

Only your last vote counts. Simply find the control # on our lightly shaded Blue Voting Instruction Form. This is the voting form that has the Shareholder Nominees on it. Then call (800) 454-8683 or go to and input your control # when prompted. It is that simple to vote or to change your vote.

You may also call the Shareholder Nominees' proxy solicitor, The Altman Group, toll free at (866) 796-7175, if you have any questions or need assistance. Finally, Mr. Karkus welcomes all calls to discuss the Company and its future with any or shareholders. He is available at (516) 569-9999.

Shareholders can access the Shareholder Nominees' proxy material and the court's opinion at

Important Additional Information

Ted Karkus, Mark Burnett, John DeShazo, Mark Frank, Louis Gleckel, MD, Mark Leventhal and James McCubbin (the "Shareholder Nominees") filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") on May 1, 2009 in connection with the 2009 Annual Meeting of Stockholders of The Quigley Corporation. Stockholders are strongly advised to read the Shareholder Nominees' proxy statement as it contains important information. Stockholders may obtain an additional copy of the Shareholder Nominee's definitive proxy statement and any other documents filed by them with the SEC for free at the SEC's website at Additionally, copies of the definitive proxy statement are available for free at

SOURCE Ted Karkus
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Federal District Judge Dismisses Antitrust Lawsuit Against Batesville Casket Company
2. Asbestos Judges, Attorneys Holding Judicial Forum June 3
3. Judge Holds Maryland Damages Cap Not Applicable to Malpractice Cases
4. Public Health is No. 1, Says U.S. District Judge in Denial of FMC Motion to Shelve the LA-LB Clean Trucks Programs
5. "Im In" - Duncan Bannatyne Judges "Switch Ash for Cash" Schools Competition
6. Public forum at Rice with mayor and county judge marks 6-month Ike anniversary
7. Judges, Doctors Featured at Mealeys Asbestos Conference in March
8. Magistrate Judge Recommends Denial of Class Certification in Funeral Industry Antitrust Litigation
9. URAC Reveals Distinguished Judges Panel for 2009 Best Practices in Health Care Consumer Empowerment and Protection Awards
10. Brain Slow to Judge Fast-Moving Objects Head-On
11. Study shows physician judgement important in reducing RSV-related hospitalizations
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
Breaking Medicine Technology: